ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gevo, Butamax Patent Fight Drags On

by Melody M. Bomgardner
March 19, 2012 | APPEARED IN VOLUME 90, ISSUE 12

Gevo and Butamax, two producers of biobased isobutyl alcohol, have filed new patent infringement lawsuits against each other. Butamax is a joint venture between DuPont and BP. Gevo and Butamax each claim to have patents covering modified enzymes that optimize production of isobutyl alcohol from sugar via fermentation by proprietary microbes. In the latest salvo of the dispute, Butamax filed a patent infringement lawsuit on March 12 against Gevo for using a family of recombinant enzymes called KARI, and Gevo immediately countersued. Butamax says the KARI enzyme performs the second step of the pathway that is fundamental to achieving high isobutyl alcohol yield.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment